致癌与突变杂志

抽象的

Patient with Primary T790M Mutation in Lung Adenocarcinoma Treated with Gefitinib as a First-Line and Osimertinib as a Second-Line Therapy: A Case Report

Daliborka Bursac, Tatjana Sarcev, Danica SazdanicVelikic, Nevena Djukic, Vanesa Sekurus, Svetlana Petkov and Goran Stojanovic

The identification of Epidermal Growth Factor Receptor (EGFR) mutations represents a major milestone in the treatment of advanced non-small-cell lung cancer. The activating mutations of EGFR occur in 10%-15% NSCLC Caucasian and 30%-40% East Asian patients, approximately. The EGFR T790M mutation is present in approximately 50%-60% of resistant cases as a secondary mutation, but as a primary less than 1%. Treatment with thyrosine kinase inhibitors (TKIs) is more efficient with fewer side effects compared with classic treatment modalities. We reported a rare case lung adenocarcinoma patient with primary T790M mutation treated with gefitinib as a fist line and osimertinib as a second line therapy.